Current Research
Research involving triacetin supplementation has shown promise in a rat model. Triacetin, which can be enzymatically cleaved to form acetate, enters the brain more readily than the negatively charged acetate. The defective enzyme in Canavan disease, aspartoacylase, converts N-acetylaspartate into aspartate and acetate. Mutations in the gene for aspartoacylase prevent the breakdown of N-acetylaspartate, and reduce brain acetate availability during brain development. Acetate supplementation using Triacetin is meant to provide the missing acetate so that brain development can continue normally.
A team of researchers headed by Paola Leone are currently at the University of Medicine and Dentistry of New Jersey, in Stratford, New Jersey. The brain gene therapy is conducted at Cooper University Hospital. The procedure involves the insertion of six catheters into the brain that deliver a solution containing 600 billion to 900 billion engineered virus particles. The virus, a modified version of AAV, is designed to replace the aspartoacylase enzyme. Children treated with this procedure to date have shown marked improvements, including the growth of myelin with decreased levels of the n-acetyl-aspartate toxin.
Read more about this topic: Canavan Disease
Famous quotes containing the words current and/or research:
“We hear the haunting presentiment of a dutiful middle age in the current reluctance of young people to select any option except the one they feel will impinge upon them the least.”
—Gail Sheehy (b. 1937)
“To be sure, nothing is more important to the integrity of the universities ... than a rigorously enforced divorce from war- oriented research and all connected enterprises.”
—Hannah Arendt (1906–1975)